Video

Dr. Falchi on the Use of Epcoritamab with R-CHOP Therapy in High-Risk DLBCL

Lorenzo Falchi, MD, discusses the updated findings from the phase 1/2 EPCORE NHL-2 trial trial evaluating the subcutaneous administration of epcoritamab with R-CHOP in patients with high-risk diffuse large B-cell lymphoma.

Lorenzo Falchi, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the updated findings from the phase 1/2 EPCORE NHL-2 trial (NCT04663347) trial evaluating the subcutaneous administration of epcoritamab with R-CHOP (rituximab [Rituxan], cyclophosphamide, doxorubicin, vincristine, and prednisone) in patients with high-risk diffuse large B-cell lymphoma (DLBCL).

The study has enrolled 33 patients and recruitment is ongoing, Falchi says. The patient population comprises those with classic, high-risk DLBCL, with 24% of patients presenting with aggressive lymphoma subtypes, Falchi adds. This high-risk population would not be expected to yield sufficient results with standard-of-care R-CHOP therapy, Falchi explains.

Epcoritamab, a bispecific antibody, has previously demonstrated efficacy in relapsed/refractory aggressive B-cell non-Hodgkin lymphomas as a single agent. Its distinct mechanism of action makes it well-suited for combination with R-CHOP.

At a median follow-up of 6.9 months, approximately 75% of patients remained on therapy and 2 patients had disease progression, Falchi concludes.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity